Skip to main content
Jacobio Pharmaceuticals Group Co., Ltd. logo

Jacobio Pharmaceuticals Group Co., Ltd. — Investor Relations & Filings

Ticker · 1167 ISIN · KYG4987A1094 LEI · 836800ZEHY59DQTEOW40 HKEX Manufacturing
Open in API
Filings indexed 310 across all filing types
Latest filing 2026-05-21 Transaction in Own Shar…
Country KY Cayman Islands
Listing HKEX 1167

About Jacobio Pharmaceuticals Group Co., Ltd.

http://www.jacobiopharma.com

Jacobio Pharmaceuticals Group Co., Ltd. is a biopharmaceutical company specializing in the in-house discovery and development of innovative oncology therapies. The company is committed to providing breakthrough treatment solutions for patients by focusing its research and development pipeline on six major tumor signaling pathways: KRAS, Tumor Immunity, Tumor Metabolism, P53, RB, and MYC. Jacobio utilizes advanced drug discovery platforms, including induced allosteric mechanisms, to develop novel and improved medicines. The company primarily focuses on developing new drugs at the clinical stage, with the strategic goal of positioning its core projects among the top three globally in their respective therapeutic areas.

Recent filings

Filing Released Lang Actions
NEXT DAY DISCLOSURE RETURN
Transaction in Own Shares Classification · 87% confidence The document is a Hong Kong Stock Exchange ‘Next Day Disclosure Return’ (Form FF305) detailing changes in issued shares, treasury shares, and a share repurchase program. It contains detailed repurchase figures, dates, prices, and confirmations by an authorized officer. This is not merely an announcement of a report, nor is it a full financial report. Rather, it is a regulatory filing disclosing the company’s buyback of its own shares. According to the classification definitions, this fits “Transaction in Own Shares” (POS).
2026-05-21 English
NEXT DAY DISCLOSURE RETURN
Transaction in Own Shares Classification · 95% confidence The document is a Next Day Disclosure Return (FF305) under Hong Kong listing rules, detailing changes in issued shares, share repurchases (treasury shares), and repurchase report. This is a mandatory regulatory disclosure of the company’s own share transactions. It does not present full financial statements or an earnings overview but focuses exclusively on share buybacks and treasury share movements. Therefore, it is classified as a Transaction in Own Shares (POS).
2026-05-20 English
NEXT DAY DISCLOSURE RETURN
Regulatory Filings
2026-05-19 English
VOLUNTARY ANNOUNCEMENT SHARE REPURCHASE AND CASH RESERVE UPDATE
Regulatory Filings
2026-05-19 English
NEXT DAY DISCLOSURE RETURN
Transaction in Own Shares Classification · 97% confidence The document is a Hong Kong Stock Exchange Next Day Disclosure Return (Form FF305) detailing changes in issued shares and treasury shares, specifically reporting the on-market repurchase of 82,800 shares and updated balances. This is a direct report of the company's own share transactions (buybacks) under Listing Rule 13.25A/17.27A. According to the classification definitions, this falls under "Transaction in Own Shares" (Code: POS).
2026-05-18 English
NEXT DAY DISCLOSURE RETURN
Transaction in Own Shares Classification · 88% confidence The document is a Hong Kong Stock Exchange Next Day Disclosure Return (Form FF305) detailing a share repurchase (buyback) and changes in treasury/issued shares by Jacobio Pharmaceuticals Group Co., Ltd. under Listing Rules (on-market repurchases, treasury share changes). This is a report of transactions in the company’s own shares. Therefore, it falls under the ‘Transaction in Own Shares’ category (Code: POS).
2026-05-14 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.